Prostatic Cancer Staging — An Overview

  • L. Andersson
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


As in all malignant disease an accurate characterization of the tumour is mandatory to predict the prognosis and to guide the treatment. Most urologists and oncologists feel today that the malignancy grade is the most important parameter in the evaluation of tumour aggressiveness. Therapeutic decisions also imply assessment of the tumour extent.


Acid Phosphatase Activity Tumour Extent Malignancy Grade Palpable Tumour Lymph Node Dissemination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W.F. Whitmore, Jr., Hormone therapy in prostatic cancer, Amer. J. Med. 21:697 (1956).PubMedCrossRefGoogle Scholar
  2. 2.
    W.J. Catalona and W.W. Scott, Carcinoma of the prostate: A review, J. Urol. 119:1 (1978).PubMedGoogle Scholar
  3. 3.
    R.J. Correa, R.G Anderson, R.P. Gibbons, and J. Tate Mason, Latent carcinoma of the prostate — why the controversy?, J. Urol. 111:644 (1974).PubMedGoogle Scholar
  4. 4.
    P.F. Denoix, Presentation d’une nomenclature classification des cancers basée sur un atlas, Acta Unio Internat. contra cancrum 9:769 (1953).Google Scholar
  5. 5.
    H.J. Jewett, Significance of the palpable prostatic nodule, J.A.M.A. 160:838 (1956).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • L. Andersson
    • 1
  1. 1.Karolinska sjukhusetStockholmSweden

Personalised recommendations